InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-33.5%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Newman James W. Jr., Director. Director active across 1 company, notably Adial Pharmaceuticals, INC.. Cumulatively, 2 disclosures have been published. Split: 2 buys · 0 sell. Total volume traded: €49k. History available since 26 November 2021. The latest transaction was disclosed on 30 December 2021 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Newman James W. Jr.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
10,000 shares@ US$2.660.79% mcap24.0% of flowCommon StockSEC:0001213900-22-000067:0
Canonical exit: 30 Mar 2022 (T+90)
10,000 shares@ US$2.850.86% mcap26.0% of flowCommon StockSEC:0001213900-21-062465:0
Canonical exit: 24 Feb 2022 (T+90)
2 of 2 declarations
About Newman James W. Jr.
James W. Newman Jr. is a Director at ADIAL PHARMACEUTICALS, INC. He oversees the company's activities and participates in strategic decision-making. His expertise in the pharmaceutical field allows him to make significant contributions to the company's governance.
